FDA's DTC Dragnet Targets Illumina, but Affy Not Named Despite Having DTC Customers | GenomeWeb

By Justin Petrone

As part of its recent investigation into direct-to-consumer genetic tests, the US Food and Drug Administration last week sent letters to DTC firms 23andMe, Decode Genetics, Knome, and Navigenics, as well as to Illumina, requesting information on why they believe their tests or platforms do not need to be cleared by the agency.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.